MD ANAMUL HAQUE

Mr. MD ANAMUL HAQUE

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2025 in Processes
Verified
Journal Article
Open access
PDF file
MHMD ANAMUL HAQUE
MD ANAMUL HAQUE
ASArchana Shrestha
Archana Shrestha
George MattheolabakisGeorge Mattheolabakis
George Mattheolabakis
Lipid nanoparticle (LNP)-based delivery systems are promising tools for advancing RNA-based therapies. However, there are underlying challenges for the oral delivery of LNPs. In this study, we optimized an LNP formulation, which we encapsulated in a pH-sensitive Eudragit® S 100 (Eu) coating. LNPs were prepared using the DLin-MC3-DMA ionizable lipid, cholesterol, DMG-PEG, and DSPC at a molar ratio of 50:38.5:10:1.5. LNPs were coated with 1% Eu solution via nanoprecipitation using 0.25% acetic acid to get Eu-coated LNPs (Eu-LNPs). Particle characteristics of LNPs were determined by using dynamic light scattering (DLS). Ribogreen and agarose gel retardation assays were used to evaluate nucleic acid entrapment and stability. LNPs and Eu-LNPs were ~120 nm and 4.5 μm in size, respectively. Eu-LNPs decrease to an average size of ~191 ± 22.9 nm at a pH of 8. Phosphate buffer (PB)-treated and untreated Eu-LNPs and uncoated LNPs were transfected in HEK-293 cells. PB-treated Eu-LNPs showed significant transfection capability compared to their non-PB-treated counterparts. Eu-LNPs protected their nucleic acid payloads in the presence of a simulated gastric fluid (SGF) with pepsin and maintained transfection capacity following SGF or simulated intestinal fluid. Hence, Eu coating is a potentially promising approach for the oral administration of LNPs.

12 June 2023 in Processes
Verified
Journal Article
Open access
PDF file
ASArchana Shrestha
Archana Shrestha
MHMD ANAMUL HAQUE
MD ANAMUL HAQUE
George MattheolabakisGeorge Mattheolabakis
George Mattheolabakis
Administration through the respiratory tract can be advantageous, with high drug bioavailability, limited enzymatic activity, reduced dose requirements compared to oral, and potentially diminished side effects. Among the different types of drugs studied for pulmonary delivery, genetic material delivery has gained favorable scientific interest, using polymer-, lipid-, inorganic-, or vector-based nanocarriers. As pulmonary drug delivery has been associated with challenges, including physiological barriers and lung metabolism, the delivery of sensitive molecules such as nucleic acids can exacerbate these challenges. While short-interfering RNAs (siRNAs) have been extensively reported as suitable ribonucleic acid interference (RNAi) candidates for pulmonary delivery, discussion on micro-RNA (miR) pulmonary delivery is limited despite their significant therapeutic potential. Recently, these non-coding RNAs have been explored in targeted or non-targeted pulmonary administration against various diseases. This review addresses the information gap on miR-pulmonary delivery with updated and concentrated literature. We briefly discuss the barriers to lung administration, describe different functional nanocarriers for miR delivery, and provide an extensive literature update on the different miRs and their targeted diseases currently being studied.

19 October 2026 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
MHMD ANAMUL HAQUE
MD ANAMUL HAQUE
ASArchana Shrestha
Archana Shrestha
George MattheolabakisGeorge Mattheolabakis
George Mattheolabakis
Background: Lipid nanoparticle (LNP) systems have emerged as leading platforms for nucleic acid delivery, with high transfection, biocompatibility, and clinical success in RNA therapeutics. However, oral nucleic acid delivery remains a major challenge, as nucleic acids and LNPs are highly susceptible to degradation under gastrointestinal (GI) conditions, which includes acidic pH, digestive enzymes, and bile salts. To address these limitations, we developed Eudragit® S 100-coated lipid nanoparticles (Eu-LNPs) as a pH-responsive system for oral nucleic acid delivery. Methods: We optimized LNPs formulated with the ionizable lipid SM-102, with and without Eu coating, by varying the nitrogen-to-phosphate (N/P) ratio, and evaluated them in vitro and in vivo. Results: Increasing the N/P ratio (3–10) significantly improved encapsulation, with N/P 10 achieving the highest nucleic acid loading while slightly reducing particle size and maintaining low polydispersity. Using a model luciferase-expressing mRNA, SM-102-based LNPs exhibited strong transfection in HEK-293 cells, with the highest luminescence-to-viability ratio observed at N/P 6. Similarly, using a GFP-expressing mRNA, strong GFP fluorescence was also observed in HEK-293, SW480, and RAW 264.7 cells, confirming efficient intracellular delivery. Subsequently, we coated the LNPs with Eudragit® S 100 to form Eu-LNPs. The coated nanoparticles preserved the encapsulated mRNA integrity for up to 7 days at 4 °C. In vivo studies in C57BL/6 mice showed that orally administered eGFP mRNA-loaded Eu-LNPs increased GFP fluorescence signal throughout the GI tract, whereas uncoated LNPs showed a negligible difference in fluorescence compared to the control. Conclusions: Overall, this study demonstrates that Eudragit® S 100-coated LNPs represent a promising approach for oral RNA delivery to the GI tract.

24 August 2025
Verified
Book Chapter
Closed access
PDF file
ASArchana Shrestha
Archana Shrestha
MHMD ANAMUL HAQUE
MD ANAMUL HAQUE
George MattheolabakisGeorge Mattheolabakis
George Mattheolabakis